Date: 2013-11-04
Type of information: Collaboration agreement
Compound: ADX71441, ADX88178
Company: Addex Therapeutics (Switzerland) National Institute on Drug Abuse (NIDA) (USA)
Therapeutic area: CNS diseases
Type agreement: collaboration
Action mechanism:
Disease: drug abuse, addiction
Details: * On November 4, 2013, Addex Therapeutics, a Swiss company pioneering allosteric modulation-based drug discovery and development, has announced a collaboration with the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH) to evaluate the pharmacology of ADX71441, a GABAB receptor positive allosteric modulator (PAM), and ADX88178, an mGlu4 PAM in preclinical models of drug abuse and addiction. The collaboration will evaluate Addex drug candidates, ADX71441 and ADX88178 in a battery of preclinical models to study their potential as treatments for nicotine and cocaine addiction.
Both pre-clinical and clinical data suggest that activation of GABAB receptors offers a unique therapeutic opportunity to address the needs of drug abuse patients by reducing drug intake, by maintaining abstinence, and by reducing drug craving. Moreover treatment with a GABAB activator can alleviate many physical signs (GI/urinary disturbances) and emotional symptoms (anxiety) associated with withdrawal. Addex recently reported positive data with ADX71441 in two models of alcohol abuse in mice, the ethanol binge-like drinking, drinking-in-the-dark (DID) and a model of long-term, excessive drinking, intermittent access to alcohol (IAA). The data have been published online on August 22 (L.S. Hwa et al. Psychopharmacology).
Financial terms:
Latest news:
